Abstract
Over the last decade, major depressive disorder (MDD) has attracted great attention in the Western societies for mainly two reasons. First, epidemiological studies demonstrate a steady increase in the number of affected patients so that MDD will be one of the most disabling conditions worldwide in the near future. Second, preclinical and clinical science has early recognized the need for elaborating the cause and progression of MDD in order to improve treatment strategies. Progress in developing advanced technologies such as DNA microarrays and next-generation sequencing has allowed for rapidly acquiring detailed biochemical information about DNA polymorphisms and transcriptome profiles. These studies collectively show profound biochemical changes in affected individuals, and animal studies partly corroborate or complement the alterations identified in patients. In this review, we survey transcriptional changes in the course of MDD and the effects of antidepressant drugs on multiple disease-related transcriptional pathways. The combination of both potentially unravels additional mechanisms of disease aetiology which eventually represents a bottom-up approach for the discovery of newly-acting antidepressant drugs.
Keywords: Major depression, serotonin/norepinephrine re-uptake inhibitor, neuroplasticity, gene arrays, Depression, Antidepressant Transcriptomics, major depressive disorder, MDD, bipolar disorder, Glutamate Transporter , neurotoxicity, neurotrophin-3, CREB-associated CBP, hormone receptors, Neuropsychopharmacology
Current Psychopharmacology
Title:Interrelation of Major Depression and Antidepressant Transcriptomics
Volume: 1
Author(s): Jurgen Zschocke, Nils Christian Gassen and Theo Rein
Affiliation:
Keywords: Major depression, serotonin/norepinephrine re-uptake inhibitor, neuroplasticity, gene arrays, Depression, Antidepressant Transcriptomics, major depressive disorder, MDD, bipolar disorder, Glutamate Transporter , neurotoxicity, neurotrophin-3, CREB-associated CBP, hormone receptors, Neuropsychopharmacology
Abstract: Over the last decade, major depressive disorder (MDD) has attracted great attention in the Western societies for mainly two reasons. First, epidemiological studies demonstrate a steady increase in the number of affected patients so that MDD will be one of the most disabling conditions worldwide in the near future. Second, preclinical and clinical science has early recognized the need for elaborating the cause and progression of MDD in order to improve treatment strategies. Progress in developing advanced technologies such as DNA microarrays and next-generation sequencing has allowed for rapidly acquiring detailed biochemical information about DNA polymorphisms and transcriptome profiles. These studies collectively show profound biochemical changes in affected individuals, and animal studies partly corroborate or complement the alterations identified in patients. In this review, we survey transcriptional changes in the course of MDD and the effects of antidepressant drugs on multiple disease-related transcriptional pathways. The combination of both potentially unravels additional mechanisms of disease aetiology which eventually represents a bottom-up approach for the discovery of newly-acting antidepressant drugs.
Export Options
About this article
Cite this article as:
Zschocke Jurgen, Christian Gassen Nils and Rein Theo, Interrelation of Major Depression and Antidepressant Transcriptomics, Current Psychopharmacology 2012; 1 (4) . https://dx.doi.org/10.2174/2211556011201040284
DOI https://dx.doi.org/10.2174/2211556011201040284 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Dietary Prevention of Cancer: Anticancer and Antiangiogenic Properties of Green Tea Polyphenols
Medicinal Chemistry Reviews - Online (Discontinued) The Bacterial lux Reporter System: Applications in Bacterial Localisation Studies
Current Gene Therapy The 1,4-Dihydropyridine Nucleus: A Pharmacophoric Template Part 1. Actions at Ion Channels
Mini-Reviews in Medicinal Chemistry Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Snake Venom L-Amino Acid Oxidases: Some Consideration About their Functional Characterization
Protein & Peptide Letters Expression of P-gp in Glioblastoma: What we can Learn from Brain Development
Current Pharmaceutical Design Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery A Novel Polyarginine Containing Smac Peptide Conjugate that Mediates Cell Death in Tumor and Healthy Cells
Medicinal Chemistry Nerve Growth Factor: Early Studies and Recent Clinical Trials
Current Neuropharmacology Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Anti-cancer Drug Discovery: Update and Comparisons in Yeast, Drosophila, and Zebrafish
Current Molecular Pharmacology Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Nanoparticle-Based Tumor Theranostics with Molecular Imaging
Current Pharmaceutical Biotechnology Advances in Molecular Therapeutic Approaches to Patients with Malignant Gliomas
Current Signal Transduction Therapy Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry